Retraction notice to "Multiple inflammatory pathways are involved in the development and progression of cognitive deficits in APPswe/PS1dE9 mice" [Neurobiol. Aging 33 (2012) 2661-2677];Multiple inflammatory pathways are involved in the development and progression of cognitive deficits in APPswe/PS1dE9 mice

Neurobiology of Aging

Volumn 33, Issue 11, 2012, Pages 2661-2677

  Zhang, Wei ^a   Bai, Miao ^a   Xi, Ye ^a   Hao, Jian ^a   Zhang, Zhuo ^a   Su, Changjun ^a   Lei, Gesheng ^a   Miao, Jianting ^a   Li, Zhuyi ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Amyloid beta protein; Cognitive deficits; Inflammation; Transgenic mice

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA;

AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; COGNITIVE DEFECT; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; FEMALE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; LEARNING DISORDER; MAZE TEST; MEMORY DISORDER; MOUSE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL;

EID: 84865608786     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2016.01.005     Document Type: Erratum

References (98)

1. Abbas N., Bednar I., Mix E., Marie S., Paterson D., Ljungberg A., Morris C., Winblad B., Nordberg A., Zhu J. Up-regulation of the inflammatory cytokines IFN-gamma and IL-12 and down-regulation of IL-4 in cerebral cortex regions of APP(SWE) transgenic mice. J. Neuroimmunol. 2002, 126:50-57.
2. Abramov A.Y., Duchen M.R. The role of an astrocytic NADPH oxidase in the neurotoxicity of amyloid beta peptides. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2005, 360:2309-2314.
3. Lyketsos C.G., Breitner J.C., Green R.C., Martin B.K., Meinert C., Piantadosi S., Sabbagh M. Naproxen and celecoxib do not prevent Alzheimer's disease (AD) in early results from a randomized controlled trial. Neurology 2007, 22:1800-1808. ADAPT Research Group.
4. Agostinho P., Cunha R.A., Oliveira C. Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer's disease. Curr. Pharm. Des. 2010, 16:2766-2778.
5. Aisen P.S., Davis K.L., Berg J.D., Schafer K., Campbell K., Thomas R.G., Weiner M.F., Farlow M.R., Sano M., Grundman M., Thal L.J. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology 2000, 54:588-593.
6. Aisen P.S., Marin D.B., Brickman A.M., Santoro J., Fusco M. Pilot tolerability studies of hydroxychloroquine and colchicine in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2001, 15:96-101.
7. Aisen P.S., Schafer K.A., Grundman M., Pfeiffer E., Sano M., Davis K.L., Farlow M.R., Jin S., Thomas R.G., Thal L.J. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003, 289:2819-2826. Alzheimer's Disease Cooperative Study.
8. Aisen P.S., Schmeidler J., Pasinetti G.M. Randomized pilot study of nimesulide treatment in Alzheimer's disease. Neurology 2002, 58:1050-1054.
9. Alafuzoff I., Overmyer M., Helisalmi S., Soininen H. Lower counts of astroglia and activated microglia in patients with Alzheimer's disease with regular use of non-steroidal anti-inflammatory drugs. J. Alzheimers Dis. 2000, 2:37-46.
10. Blasko I., Marx F., Steiner E., Hartmann T., Grubeck-Loebenstein B. TNFalpha plus IFNgamma induce the production of Alzheimer beta-amyloid peptides and decrease the secretion of APPs. FASEB J. 1999, 13:63-68.
11. Cuello A.C., Ferretti M.T., Leon W.C., Iulita M.F., Melis T., Ducatenzeiler A., Bruno M.A., Canneva F. Early-stage inflammation and experimental therapy in transgenic models of the Alzheimer-like amyloid pathology. Neurodegener. Dis. 2010, 7:96-98.
12. Cumiskey D., Butler M.P., Moynagh P.N., O'Connor J.J. Evidence for a role for the group I metabotropic glutamate receptor in the inhibitory effect of tumor necrosis factor-alpha on long-term potentiation. Brain Res. 2007, 1136:13-19.
13. Curran B.P., O'Connor J.J. The inhibition of long-term potentiation in the rat dentate gyrus by pro-inflammatory cytokines is attenuated in the presence of nicotine. Neurosci. Lett. 2003, 344:103-106.
14. D'Andrea M.R., Cole G.M., Ard M.D. The microglial phagocytic role with specific plaque types in the Alzheimer disease brain. Neurobiol. Aging 2004, 25:675-683.
15. DaRocha-Souto B., Scotton T.C., Coma M., Serrano-Pozo A., Hashimoto T., Serenó L., Rodríguez M., Sánchez B., Hyman B.T., Gómez-Isla T. Brain oligomeric β-amyloid but not total amyloid plaque burden correlates with neuronal loss and astrocyte inflammatory response in amyloid precursor protein/tau transgenic mice. J. Neuropathol. Exp. Neurol. 2011, 70:360-376.
16. de Jong D., Jansen R., Hoefnagels W., Jellesma-Eggenkamp M., Verbeek M., Borm G., Kremer B. No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial. PLoS One 2008, 3:e1475.
17. Del Bo R., Angeretti N., Lucca E., De Simoni M.G., Forloni G. Reciprocal control of inflammatory cytokines, IL-1 and IL-6, and beta-amyloid production in cultures. Neurosci. Lett. 1995, 188:70-74.
18. Dudal S., Krzywkowski P., Paquette J., Morissette C., Lacombe D., Tremblay P., Gervais F. Inflammation occurs early during the Abeta deposition process in TgCRND8 mice. Neurobiol. Aging 2004, 25:861-871.
19. Edison P., Archer H.A., Gerhard A., Hinz R., Pavese N., Turkheimer F.E., Hammers A., Tai Y.F., Fox N., Kennedy A., Rossor M., Brooks D.J. Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol. Dis. 2008, 32:412-419.
20. Eriksen J.L., Sagi S.A., Smith T.E., Weggen S., Das P., McLendon D.C., Ozols V.V., Jessing K.W., Zavitz K.H., Koo E.H., Golde T.E. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J. Clin. Invest. 2003, 112:440-449.
21. Fan R., Xu F., Previti M.L., Davis J., Grande A.M., Robinson J.K., Van Nostrand W.E. Minocycline reduces microglial activation and improves behavioral deficits in a transgenic model of cerebral microvascular amyloid. J. Neurosci. 2007, 27:3057-3063.
22. Ferretti M.T., Bruno M.A., Ducatenzeiler A., Klein W.L., Cuello A.C. Intracellular Aβ-oligomers and early inflammation in a model of Alzheimer's disease. Neurobiol. Aging. 2011, Epub ahead of print. 10.1016/j.neurobiolaging.2011.01.007.
23. Ferretti M.T., Cuello A.C. Does a pro-inflammatory process precede Alzheimer's disease and mild cognitive impairment?. Curr. Alzheimer Res. 2011, 8:164-174.
24. Garcia-Alloza M., Robbins E.M., Zhang-Nunes S.X., Purcell S.M., Betensky R.A., Raju S., Prada C., Greenberg S.M., Bacskai B.J., Frosch M.P. Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol. Dis. 2006, 24:516-524.
25. Garwood C.J., Pooler A.M., Atherton J., Hanger D.P., Noble W. Astrocytes are important mediators of Aβ-induced neurotoxicity and tau phosphorylation in primary culture. Cell. Death Dis. 2011, 2:e167.
26. Gasparini L., Ongini E., Wenk G. Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer's disease: old and new mechanisms of action. J. Neurochem. 2004, 91:521-536.
27. Glabe C.G. Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiol. Aging 2006, 27:570-575.
28. Halliday G.M., Shepherd C.E., McCann H., Reid W.G., Grayson D.A., Broe G.A., Kril J.J. Effect of anti-inflammatory medications on neuropathological findings in Alzheimer disease. Arch. Neurol. 2000, 57:831-836.
29. Hardy J.A., Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256:184-185.
30. Heneka M.T., Kummer M.P., Weggen S., Bulic B., Multhaup G., Münter L., Hüll M., Pflanzner T., Pietrzik C.U. Molecular mechanisms and therapeutic application of NSAIDs and derived compounds in Alzheimer's disease. Curr. Alzheimer Res. 2011, 8:115-131.
31. Heneka M.T., O'Banion M.K., Terwel D., Kummer M.P. Neuroinflammatory processes in Alzheimer's disease. J. Neural Transm. 2010, 117:919-947.
32. Heneka M.T., Sastre M., Dumitrescu-Ozimek L., Dewachter I., Walter J., Klockgether T., Van Leuven F. Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP[V717I] transgenic mice. J. Neuroinflammation 2005, 2:22.
33. Hensley K. Neuroinflammation in Alzheimer's disease: mechanisms, pathologic consequences, and potential for therapeutic manipulation. J. Alzheimers Dis. 2010, 21:1-14.
34. Hoshino T., Nakaya T., Homan T., Tanaka K., Sugimoto Y., Araki W., Narita M., Narumiya S., Suzuki T., Mizushima T. Involvement of prostaglandin E2 in production of amyloid-beta peptides both in vitro and in vivo. J. Biol. Chem. 2007, 282:32676-32688.
35. Hoshino T., Namba T., Takehara M., Nakaya T., Sugimoto Y., Araki W., Narumiya S., Suzuki T., Mizushima T. Prostaglandin E2 stimulates the production of amyloid-beta peptides through internalization of the EP4 receptor. J. Biol. Chem. 2009, 284:18493-18502.
36. Imbimbo B.P. An update on the efficacy of non-steroidal anti-inflammatory drugs in Alzheimer's disease. Expert Opin. Investig. Drugs 2009, 18:1147-1168.
37. Imbimbo B.P., Giardino L., Sivilia S., Giuliani A., Gusciglio M., Pietrini V., Del Giudice E., D'Arrigo A., Leon A., Villetti G., Calzà L. CHF5074, a novel gamma-secretase modulator, restores hippocampal neurogenesis potential and reverses contextual memory deficit in a transgenic mouse model of Alzheimer's disease. J. Alzheimers Dis. 2010, 20:159-173.
38. Imbimbo B.P., Solfrizzi V., Panza F. Are NSAIDs useful to treat Alzheimer's disease or mild cognitive impairment?. Front. Aging Neurosci. 2010, 2. pii 19.
39. In T' Veld B.A., Ruitenberg A., Hofman A., Launer L.J., van Duijn C.M., Stijnen T., Breteler M.M., Stricker B.H. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J. Med. 2001, 345:1515-1521.
40. Janelsins M.C., Mastrangelo M.A., Oddo S., LaFerla F.M., Federoff H.J., Bowers W.J. Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer's disease mice. J. Neuroinflammation 2005, 2:23.
41. Johnston H., Boutin H., Allan S.M. Assessing the contribution of inflammation in models of Alzheimer's disease. Biochem. Soc. Trans. 2011, 39:886-890.
42. Kitazawa M., Oddo S., Yamasaki T.R., Green K.N., LaFerla F.M. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J. Neurosci. 2005, 25:8843-8853.
43. Koch H., Huh S.E., Elsen F.P., Carroll M.S., Hodge R.D., Bedogni F., Turner M.S., Hevner R.F., Ramirez J.M. Prostaglandin E2-induced synaptic plasticity in neocortical networks of organotypic slice cultures. J. Neurosci. 2010, 30:11678-11687.
44. Lee J.W., Lee Y.K., Yuk D.Y., Choi D.Y., Ban S.B., Oh K.W., Hong J.T. Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of beta-amyloid generation. J. Neuroinflammation 2008, 5:37.
45. Lee S., Fernandez E.J., Good T.A. Role of aggregation conditions in structure, stability, and toxicity of intermediates in the Abeta fibril formation pathway. Protein Sci. 2007, 16:723-732.
46. Lee Y.J., Choi D.Y., Choi I.S., Han J.Y., Jeong H.S., Han S.B., Oh K.W., Hong J.T. Inhibitory effect of a tyrosine-fructose Maillard reaction product, 2,4-bis(p-hydroxyphenyl)-2-butenal on amyloid-β generation and inflammatory reactions via inhibition of NF-κB and STAT3 activation in cultured astrocytes and microglial BV-2 cells. J. Neuroinflammation 2011, 8:132.
47. Li A.J., Katafuchi T., Oda S., Hori T., Oomura Y. Interleukin-6 inhibits long-term potentiation in rat hippocampal slices. Brain Res. 1997, 748:30-38.
48. Li N., Liu G.T. The novel squamosamide derivative FLZ enhances BDNF/TrkB/CREB signaling and inhibits neuronal apoptosis in APP/PS1 mice. Acta Pharmacol. Sin. 2010, 31:265-272.
49. Liao Y.F., Wang B.J., Cheng H.T., Kuo L.H., Wolfe M.S. Tumor necrosis factor-alpha, interleukin-1beta, and interferon-gamma stimulate gamma-secretase-mediated cleavage of amyloid precursor protein through a JNK-dependent MAPK pathway. J. Biol. Chem. 2004, 279:49523-49532.
50. Lim G.P., Yang F., Chu T., Chen P., Beech W., Teter B., Tran T., Ubeda O., Ashe K.H., Frautschy S.A., Cole G.M. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J. Neurosci. 2000, 20:5709-5714.
51. Maat-Schieman M.L., Yamaguchi H., Hegeman-Kleinn I.M., Welling-Graafland C., Natté R., Roos R.A., van Duinen S.G. Glial reactions and the clearance of amyloid beta protein in the brains of patients with hereditary cerebral hemorrhage with amyloidosis-Dutch type. Acta Neuropathol. 2004, 107:389-398.
52. McGeer P.L., Schulzer M., McGeer E.G. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 1996, 47:425-432.
53. Meyer-Luehmann M., Spires-Jones T.L., Prada C., Garcia-Alloza M., de Calignon A., Rozkalne A., Koenigsknecht-Talboo J., Holtzman D.M., Bacskai B.J., Hyman B.T. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature 2008, 451:720-724.
54. Miao J., Vitek M.P., Xu F., Previti M.L., Davis J., Van Nostrand W.E. Reducing cerebral microvascular amyloid-beta protein deposition diminishes regional neuroinflammation in vasculotropic mutant amyloid precursor protein transgenic mice. J. Neurosci. 2005, 25:6271-6277.
55. Miao J., Zhang W., Yin R., Liu R., Su C., Lei G., Li Z. S14G-Humanin ameliorates Abeta25-35-induced behavioral deficits by reducing neuroinflammatory responses and apoptosis in mice. Neuropeptides 2008, 42:557-567.
56. Miklossy J., Kis A., Radenovic A., Miller L., Forro L., Martins R., Reiss K., Darbinian N., Darekar P., Mihaly L., Khalili K. Beta-amyloid deposition and Alzheimer's type changes induced by Borrelia spirochetes. Neurobiol. Aging 2006, 27:228-236.
57. Mohamed A., Posse de Chaves E. Aβ internalization by neurons and glia. Int. J. Alzheimers Dis. 2011, 2011:127984.
58. Murphy G.M., Zhao F., Yang L., Cordell B. Expression of macrophage colony-stimulating factor receptor is increased in the AbetaPP(V717F) transgenic mouse model of Alzheimer's disease. Am. J. Pathol. 2000, 157:895-904.
59. Murray C.A., Lynch M.A. Evidence that increased hippocampal expression of the cytokine interleukin-1 beta is a common trigger for age- and stress-induced impairments in long-term potentiation. J. Neurosci. 1998, 18:2974-2981.
60. O'Leary T.P., Brown R.E. Visuo-spatial learning and memory deficits on the Barnes maze in the 16-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease. Behav. Brain Res. 2009, 201:120-127.
61. Parachikova A., Agadjanyan M.G., Cribbs D.H., Blurton-Jones M., Perreau V., Rogers J., Beach T.G., Cotman C.W. Inflammatory changes parallel the early stages of Alzheimer disease. Neurobiol. Aging 2007, 28:1821-1833.
62. Pihlaja R., Koistinaho J., Malm T., Sikkilä H., Vainio S., Koistinaho M. Transplanted astrocytes internalize deposited beta-amyloid peptides in a transgenic mouse model of Alzheimer's disease. Glia 2008, 56:154-163.
63. Qiao X., Cummins D.J., Paul S.M. Neuroinflammation-induced acceleration of amyloid deposition in the APPV717F transgenic mouse. Eur. J. Neurosci. 2001, 14:474-482.
64. Qin L., Liu Y., Cooper C., Liu B., Wilson B., Hong J.S. Microglia enhance beta-amyloid peptide-induced toxicity in cortical and mesencephalic neurons by producing reactive oxygen species. J. Neurochem. 2002, 83:973-983.
65. Qin W., Ho L., Pompl P.N., Peng Y., Zhao Z., Xiang Z., Robakis N.K., Shioi J., Suh J., Pasinetti G.M. Cyclooxygenase (COX)-2 and COX-1 potentiate beta-amyloid peptide generation through mechanisms that involve gamma-secretase activity. J. Biol. Chem. 2003, 278:50970-50977.
66. Reines S.A., Block G.A., Morris J.C., Liu G., Nessly M.L., Lines C.R., Norman B.A., Baranak C.C. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 2004, 62:66-71. Rofecoxib Protocol 091 Study Group.
67. Ringheim G.E., Szczepanik A.M., Petko W., Burgher K.L., Zhu S.Z., Chao C.C. Enhancement of beta-amyloid precursor protein transcription and expression by the soluble interleukin-6 receptor/interleukin-6 complex. Brain Res. Mol. Brain Res. 1998, 55:35-44.
68. Rodríguez J.J., Witton J., Olabarria M., Noristani H.N., Verkhratsky A. Increase in the density of resting microglia precedes neuritic plaque formation and microglial activation in a transgenic model of Alzheimer's disease. Cell. Death Dis. 2010, 1:e1.
69. Rogers J., Kirby L.C., Hempelman S.R., Berry D.L., McGeer P.L., Kaszniak A.W., Zalinski J., Cofield M., Mansukhani L., Willson P., et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993, 43:1609-1611. etA.l.
70. Ruan L., Kang Z., Pei G., Le Y. Amyloid deposition and inflammation in APPswe/PS1dE9 mouse model of Alzheimer's disease. Curr. Alzheimer Res. 2009, 6:531-540.
71. Sastre M., Dewachter I., Rossner S., Bogdanovic N., Rosen E., Borghgraef P., Evert B.O., Dumitrescu-Ozimek L., Thal D.R., Landreth G., Walter J., Klockgether T., van Leuven F., Heneka M.T. Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:443-448.
72. Sastre M., Gentleman S.M. NSAIDs: How they Work and their Prospects as Therapeutics in Alzheimer's Disease. Front. Aging Neurosci. 2010, 2:20.
73. Sastre M., Klockgether T., Heneka M.T. Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms. Int. J. Dev. Neurosci. 2006, 24:167-176.
74. Sastre M., Walter J., Gentleman S.M. Interactions between APP secretases and inflammatory mediators. J. Neuroinflammation 2008, 5:25.
75. Savonenko A., Xu G.M., Melnikova T., Morton J.L., Gonzales V., Wong M.P., Price D.L., Tang F., Markowska A.L., Borchelt D.R. Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities. Neurobiol. Dis. 2005, 18:602-617.
76. Scharf S., Mander A., Ugoni A., Vajda F., Christophidis N. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 1999, 53:197-201.
77. Serrano-Pozo A., Mielke M.L., Gómez-Isla T., Betensky R.A., Growdon J.H., Frosch M.P., Hyman B.T. Reactive glia not only associates with plaques but also parallels tangles in Alzheimer's disease. Am. J. Pathol. 2011, 179:1373-1384.
78. Sheng J.G., Bora S.H., Xu G., Borchelt D.R., Price D.L., Koliatsos V.E. Lipopolysaccharide-induced-neuroinflammation increases intracellular accumulation of amyloid precursor protein and amyloid beta peptide in APPswe transgenic mice. Neurobiol. Dis. 2003, 14:133-145.
79. Soininen H., West C., Robbins J., Niculescu L. Long-term efficacy and safety of celecoxib in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2007, 23:8-21.
80. Stewart W.F., Kawas C., Corrada M., Metter E.J. Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997, 48:626-632.
81. Szekely C.A., Thorne J.E., Zandi P.P., Ek M., Messias E., Breitner J.C., Goodman S.N. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology 2004, 23:159-169.
82. Tancredi V., D'Antuono M., Cafè C., Giovedì S., Buè M.C., D'Arcangelo G., Onofri F., Benfenati F. The inhibitory effects of interleukin-6 on synaptic plasticity in the rat hippocampus are associated with an inhibition of mitogen-activated protein kinase ERK. J. Neurochem. 2000, 75:634-643.
83. Tancredi V., D'Arcangelo G., Grassi F., Tarroni P., Palmieri G., Santoni A., Eusebi F. Tumor necrosis factor alters synaptic transmission in rat hippocampal slices. Neurosci. Lett. 1992, 146:176-178.
84. Tehranian R., Hasanvan H., Iverfeldt K., Post C., Schultzberg M. Early induction of interleukin-6 mRNA in the hippocampus and cortex of APPsw transgenic mice Tg2576. Neurosci. Lett. 2001, 301:54-58.
85. Thal L.J., Ferris S.H., Kirby L., Block G.A., Lines C.R., Yuen E., Assaid C., Nessly M.L., Norman B.A., Baranak C.C., Reines S.A. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 2005, 30:1204. Rofecoxib Protocol 078 study group.
86. Thomas T., Nadackal T.G., Thomas K. Aspirin and non-steroidal anti-inflammatory drugs inhibit amyloid-beta aggregation. Neuroreport 2001, 12:3263-3267.
87. Vereker E., O'Donnell E., Lynch M.A. The inhibitory effect of interleukin-1beta on long-term potentiation is coupled with increased activity of stress-activated protein kinases. J. Neurosci. 2000, 20:6811-6819.
88. Versijpt J.J., Dumont F., Van Laere K.J., Decoo D., Santens P., Audenaert K., Achten E., Slegers G., Dierckx R.A., Korf J. Assessment of neuroinflammation and microglial activation in Alzheimer's disease with radiolabelled PK11195 and single photon emission computed tomography. A pilot study. Eur. Neurol. 2003, 50:39-47.
89. Wang H., Liu J., Zong Y., Xu Y., Deng W., Zhu H., Liu Y., Ma C., Huang L., Zhang L., Qin C. miR-106b aberrantly expressed in a double transgenic mouse model for Alzheimer's disease targets TGF-β type II receptor. Brain Res. 2010, 1357:166-174.
90. Weggen S., Eriksen J.L., Das P., Sagi S.A., Wang R., Pietrzik C.U., Findlay K.A., Smith T.E., Murphy M.P., Bulter T., Kang D.E., Marquez-Sterling N., Golde T.E., Koo E.H. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001, 414:212-216.
91. Wirths O., Breyhan H., Marcello A., Cotel M.C., Brück W., Bayer T.A. Inflammatory changes are tightly associated with neurodegeneration in the brain and spinal cord of the APP/PS1KI mouse model of Alzheimer's disease. Neurobiol. Aging 2010, 31:747-757.
92. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response?. Nat. Med. 2006, 12:1005-1015.
93. Yamamoto M., Kiyota T., Horiba M., Buescher J.L., Walsh S.M., Gendelman H.E., Ikezu T. Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice. Am. J. Pathol. 2007, 170:680-692.
94. Yan Q., Zhang J., Liu H., Babu-Khan S., Vassar R., Biere A.L., Citron M., Landreth G. Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J. Neurosci. 2003, 23:7504-7509.
95. Zandi P.P., Anthony J.C., Hayden K.M., Mehta K., Mayer L., Breitner J.C. Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. Neurology 2002, 59:880-886. Cache County Study Investigators.
96. Zhang D., Hu X., Qian L., Chen S.H., Zhou H., Wilson B., Miller D.S., Hong J.S. Microglial MAC1 receptor and PI3K are essential in mediating β-amyloid peptide-induced microglial activation and subsequent neurotoxicity. J. Neuroinflammation 2011, 8:3.
97. Zhang W., Hao J., Liu R., Zhang Z., Lei G., Su C., Miao J., Li Z. Soluble Aβ levels correlate with cognitive deficits in the 12-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease. Behav. Brain Res. 2011, 222:342-350.
98. Zhao J., O'Connor T., Vassar R. The contribution of activated astrocytes to Aβ production: Implications for Alzheimer's disease pathogenesis. J. Neuroinflammation 2011, 8:150.